# A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants

> **NCT01688635** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 91 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY2963016
- **DRUG:** US Approved Lantus

## Key facts

- **NCT ID:** NCT01688635
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688635, "A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT01688635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*